Centr Georges Francois Leclerc

The trials here

What the 273 trials at this site are about, from their registry records.

Conditions

• Lung cancer70 trials
• Metastatic breast cancer44 trials
• Colorectal cancer38 trials
• Liver and biliary tract cancer20 trials
• Prostate cancer20 trials
• Ovarian cancer19 trials
• Gastric and oesophageal cancer17 trials
• Pancreatic cancer17 trials
• Head and neck cancer16 trials
• Bladder cancer15 trials
• Endometrial cancer14 trials
• Sarcoma11 trials
• and 11 more

Phase

• Phase 3107 trials
• Phase 289 trials
• Phase 1/241 trials
• Phase 121 trials
• Phase 2/311 trials
• Phase 44 trials

Status

• Recruiting105 trials
• Active, not recruiting88 trials
• Completed58 trials
• Not yet recruiting18 trials
• Suspended3 trials
• Withdrawn1 trial

Lead sponsor

• UNICANCER27 trials
• AstraZeneca15 trials
• Intergroupe Francophone de Cancerologie Thoracique9 trials
• Merck Sharp & Dohme LLC9 trials
• Institut Gustave Roussy8 trials
• and 116 more

Running trials

• Recruiting

  Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression

  2025-524641-27-00· Phase 3· K-Group Beta Inc.· Source

• Not yet recruiting

  Exploratory study of the performance of dynamic PET-CT acquisition to predict 6-month morphological response in patients with hepatocellular carcinoma treated with selective internal radiotherapy

  2026-526324-48-00· Phase 1/2· Centr Georges Francois Leclerc· Source

• Not yet recruiting

  Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.

  NCT07717450· Phase 3· UNICANCER· Source

• Recruiting

  Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  NCT07680790· Phase 3· Bristol-Myers Squibb· Source

• Not yet recruiting

  Reduction of treatment after Complete Response in Advanced Hormone-Sensitive Breast Cancer

  2026-526319-12-00· Phase 3· Unicancer· Source

• Not yet recruiting

  Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

  NCT07151586· Phase 2· UNICANCER· Source

• Recruiting

  A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC

  NCT07807163· Phase 2· Bicara Therapeutics· Source

• Recruiting

  A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

  NCT07566052· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Not yet recruiting

  Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.

  2026-525883-17-00· Phase 3· Genmab A/S· Source

• Not yet recruiting

  A Phase 2 Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

  2025-523923-22-00· Phase 2· Elevar Therapeutics Inc.· Source

• Recruiting

  A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

  NCT07673887· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

  NCT07659782· Phase 2· Verastem, Inc.· Source

• Recruiting

  A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)

  2025-521587-35-00· Phase 3· Summit Therapeutics Inc.· Source

• Not yet recruiting

  Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy_POG

  2025-523610-83-00· Phase 4· Institut Gustave Roussy· Source

• Recruiting

  A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

  NCT07419295· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors-positive and HER2-negative, advanced breast cancers, resistant to CDK4/6 inhibitor plus aromatase inhibitor-based endocrine treatment and with homologous recombination deficiency, oncogenic driver activation and/or other molecular alterations associated with replication stress (RS)

  NCT05986071· Phase 1/2· Institut Paoli-Calmettes· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )

  2024-519818-31-01· Phase 3· Genmab A/S· Source

• Recruiting

  A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

  NCT07489495· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

  NCT07225270· Phase 3· Genmab· Source

• Recruiting

  Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma

  2024-519208-29-00· Phase 2· Intergroupe Francophone De Cancerologie Thoracique· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  Study aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combination of Immune checkpoint inhibitors (botensilimab + balstilimab) versus the standard of care (FOLFOX/XELOX + nivolumab)

  2023-506291-28-00· Phase 3· Centre Leon Berard· Source

• Recruiting

  Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

  NCT07371585· Phase 2· SOLTI Breast Cancer Research Group· Source

• Recruiting

  A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

  NCT07409272· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Not yet recruiting

  Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma

  NCT07347210· Phase 2· Centre Hospitalier Universitaire de Besancon· Source

• Not yet recruiting

  A phase 1, open-label, dose-escalation and dose-expansion study evaluating the safety, feasability and efficacy of ODI-2001 vaccine, a personalized immunotherapy, in patients with metastatic or locally advanced colon cancer of pancreatic cancer

  2025-523172-23-00· Phase 1· Centr Georges Francois Leclerc· Source

• Recruiting

  A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

  NCT07221474· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Recruiting

  Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

  NCT06908993· Phase 3· Intergroupe Francophone de Cancerologie Thoracique· Source

• Recruiting

  Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX

  NCT07044453· Phase 2/3· University Hospital, Rouen· Source

• Recruiting

  Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

  NCT07227012· Phase 1/2· Pfizer· Source

• Recruiting

  A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

  NCT06996782· Phase 1/2· AstraZeneca· Source

• Recruiting

  A randomized multicenter Phase II trial evaluating oral pooled fecal microbiotherapy (MaaT033) concomitant to Cemiplimab (CB) versus best investigator’s choice (BIC) in resistance to PD-1/PD-L1 blockade due to antibiotics (ATB) uptake in patients with advanced non-small cell lung cancer (NSCLC) - IMMUNOLIFE2

  2024-517018-14-00· Phase 2· Institut Gustave Roussy· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  NCT07059845· Phase 2· AbbVie· Source

• Recruiting

  Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

  NCT06656598· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Active, not recruiting

  A Study of Subcutaneous Nivolumab plus Intravenous Ipilimumab and Chemotherapy in Participants with Previously Untreated Metastatic or Recurrent NSCLC

  2024-520108-25-00· Phase 2· Bristol-Myers Squibb Services Unlimited Company· Source

• Recruiting

  Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.

  NCT07192068· Phase 2· UNICANCER· Source

• Not yet recruiting

  PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma

  NCT07128290· Phase 2· Federation Francophone de Cancerologie Digestive· Source

• Recruiting

  Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  NCT06899126· Phase 3· Daiichi Sankyo· Source

• Recruiting

  Testing ivonescimab in combination with standard chemotherapy in advanced or metastatic gastric and gastroesophageal adenocarcinoma patients

  NCT06846346· Phase 2· Unicancer· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Influence des caractéristiques morphologiques sur la pharmacocinétique et la toxicité du trastuzumab-déruxtécan chez des patients ayant un cancer du sein métastatique (TDXdose)

  2025-522656-68-00· Phase 4· Oncopole Claudius Regaud· Source

• Recruiting

  An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

  NCT07206056· Phase 1/2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC)

  2025-521681-10-00· Phase 2· Revolution Medicines Inc.· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source

• Recruiting

  Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

  NCT06757634· Phase 3· Celcuity Inc· Source

• Recruiting

  Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

  NCT06606730· Phase 3· UNICANCER· Source

Showing 50 of 211.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer28 recruiting
• Metastatic breast cancer22 recruiting
• Colorectal cancer18 recruiting
• Ovarian cancer11 recruiting
• Liver and biliary tract cancer9 recruiting
• Pancreatic cancer9 recruiting
• Prostate cancer9 recruiting
• Bladder cancer7 recruiting
• Gastric and oesophageal cancer7 recruiting
• Sarcoma7 recruiting
• Triple-negative breast cancer7 recruiting
• Endometrial cancer6 recruiting
• Childhood cancers5 recruiting
• Head and neck cancer5 recruiting
• Kidney cancer4 recruiting
• Cervical cancer1 recruiting
• Glioblastoma1 recruiting
• Melanoma1 recruiting
• Mesothelioma1 recruiting
• Thyroid cancer1 recruiting

Closed trials

• Completed

  Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults with Advanced Colorectal Cancer.

  2025-523984-39-00· Phase 2· Gilead Sciences Inc.· Source

• Not yet recruiting

  Evaluation of Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma

  NCT06933966· Phase 2· Centre Leon Berard· Source

• Recruiting

  Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC)

  2024-517819-74-00· Phase 1/2· Merck Healthcare KGaA· Source

• Completed

  Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

  2023-503218-56-00· Phase 2· Institut Gustave Roussy· Source

• Active, not recruiting

  A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

  NCT06644768· Phase 1/2· Daiichi Sankyo· Source

• Completed

  Effect of Copper CU64 PSMA I&T scanning to detect potential disease spread to lymph nodes in men with newly diagnosed Prostate Cancer

  2024-512754-16-01· Phase 3· Curium US LLC· Source

• Active, not recruiting

  A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients

  NCT06540391· Phase 1· Microbiotica Ltd· Source

• Active, not recruiting

  Volrustomig Priming Regimens Exploratory Phase II Platform Study

  NCT06448754· Phase 2· AstraZeneca· Source

• Completed

  A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

  NCT06395753· Phase 2· Debiopharm International SA· Source

• Active, not recruiting

  Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

  NCT05739942· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

  NCT06119217· Phase 2· Trishula Therapeutics, Inc.· Source

• Completed

  TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of vepdegestrant (ARV-471) in Combination With Other Medicines in Adults With ER+ Advanced or Metastatic Breast Cancer, Sub-study C (ARV-471 and Samuraciclib)

  NCT06125522· Phase 1/2· Pfizer Inc.· Source

• Completed

  A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma.

  NCT04718675· Phase 1· Kronos Bio Inc.· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatocellular Carcinoma (Morpheus-Neo HCC)

  2022-502840-11-00· Phase 1/2· F. Hoffmann-La Roche AG· Source

• Completed

  AN OPEN-LABEL, MULTICENTER, PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED, REFRACTORY, OR NEWLY DIAGNOSED CANCERS

  NCT04553692· Phase 1· IGM Biosciences Inc.· Source

• Active, not recruiting

  A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

  NCT06003231· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Recruiting

  A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors

  NCT05642780· Phase 2· Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.· Source

• Completed

  A study to investigate response to ompenaclid combined with FOLFIRI plus bevacizumab in patients with advanced or metastatic colorectal cancer

  2023-503356-27-00· Phase 2· Inspirna Inc.· Source

• Completed

  A Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Stage III and Stage IV Melanoma in the Adjuvant Setting

  2022-502620-49-00· Phase 1· Amgen Inc.· Source

• Active, not recruiting

  A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

  NCT05845814· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Evaluation of the Value of 18F-Fluoromisonidazole (18F-FMISO) Positron Emission Tomography Hypoxia Imaging in Idiopathic Pulmonary Fibrosis

  NCT05331729· Phase 1· Centre Hospitalier Universitaire Dijon· Source

• Active, not recruiting

  ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

  NCT05650879· Phase 1· Enliven Therapeutics· Source

• Completed

  A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patients with Advanced Solid Tumors and a KRAS-G12C Mutation

  NCT05480865· Phase 1· Navire Pharma Inc.· Source

• Completed

  PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patients with hepatocellular carcinoma receiving first-line systemic therapy-

  2022-501217-31-00· Phase 2/3· Fondation Franc.Cancerologie Digestive· Source

• Completed

  Clinical investigation evaluating safety and efficacy of selective intra-arterial 166Holmium radiation therapy in combination with atezolizumab and bevacizumab for non resectable Hepatocellular carcinoma (HOLMBRAVE)

  2024-511538-11-00· Phase 2· Institut Gustave Roussy· Source

• Completed

  Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)

  2023-508528-36-00· Phase 3· Merck Healthcare KGaA· Source

• Completed

  Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

  NCT05512377· Phase 2· Boehringer Ingelheim· Source

• Active, not recruiting

  Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

  NCT05609578· Phase 2· Mirati Therapeutics Inc.· Source

• Completed

  A PHASE 1/2 STUDY OF ONCOBAX®-AK ADMINISTERED IN COMBINATION WITH IMMUNOTHERAPY TO PATIENTS WITH ADVANCED SOLID TUMORS

  2024-516711-24-00· Phase 1/2· Everimmune· Source

• Active, not recruiting

  Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

  NCT05403385· Phase 2· iTeos Therapeutics· Source

• Completed

  A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorectal Cancer

  NCT05328908· Phase 3· Bristol Myers Squibb International Corporation· Source

• Active, not recruiting

  IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

  NCT05155254· Phase 3· IO Biotech· Source

• Completed

  A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

  NCT05249426· Phase 1· Boehringer Ingelheim· Source

• Active, not recruiting

  Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

  NCT05486182· Phase 4· GE Healthcare· Source

• Completed

  A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

  NCT05198804· Phase 1/2· K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc· Source

• Active, not recruiting

  OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

  NCT04713514· Phase 2· ARCAGY/ GINECO GROUP· Source

• Completed

  Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)

  NCT04736485· Phase 2· Centre Francois Baclesse· Source

• Completed

  Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

  NCT04895722· Phase 2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

  NCT04793958· Phase 3· Mirati Therapeutics Inc.· Source

• Completed

  An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

  NCT04660812· Phase 1/2· Arcus Biosciences, Inc.· Source

• Active, not recruiting

  Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

  NCT04685135· Phase 3· Mirati Therapeutics Inc.· Source

• Completed

  A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

  NCT04623775· Phase 2· Bristol-Myers Squibb· Source

• Completed

  Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations

  NCT04357873· Phase 2· UNICANCER· Source

• Completed

  REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

  NCT04526106· Phase 1/2· Elevar Therapeutics· Source

• Completed

  Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma

  NCT03875144· Phase 2· Institut Regional Du Cancer De Montpellier· Source

• Active, not recruiting

  A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

  NCT04211337· Phase 3· Loxo Oncology, Inc.· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

  NCT04191499· Phase 2/3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

  NCT04077099· Phase 1/2· Regeneron Pharmaceuticals· Source

• Completed

  A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

  NCT04026412· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

  NCT03602859· Phase 3· Tesaro, Inc.· Source

Showing 50 of 59.